Bispecific Trial in Myeloma Sparks Talks of ‘Functional Cure’

By News Health
56 minutes Ago

(MedPage Today) — ORLANDO — Combining teclistamab (Tecvayli) with subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118914

Author :

Publish date : 2025-12-09 19:35:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Parkinson's and Flu Vaccines; Sleep and Life Expectancy; Positive Duchenne Data

Unmatched Cardiology Fellowships; Long Troponin Assay; Goat Cheese and Heart Risk

Amos Flags Serious Failings in Maternity Services

Polatuzumab Vedotin With R-CHP Shows Strong Activity in Older DLBCL Patients

PA- and Physician-Led Heart Transplant Recovery Comparable

Novel Orexin Drug Improves Cognitive Symptoms of Narcolepsy Type 1